Cargando…
Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
Autores principales: | Romito, Ilaria, Porru, Manuela, Braghini, Maria Rita, Pompili, Luca, Panera, Nadia, Crudele, Annalisa, Gnani, Daniela, De Stefanis, Cristiano, Scarsella, Marco, Pomella, Silvia, Mortera, Stefano Levi, de Billy, Emmanuel, Conti, Adrian Libenzio, Marzano, Valeria, Putignani, Lorenza, Vinciguerra, Manlio, Balsano, Clara, Pastore, Anna, Rota, Rossella, Tartaglia, Marco, Leonetti, Carlo, Alisi, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793270/ https://www.ncbi.nlm.nih.gov/pubmed/35086550 http://dx.doi.org/10.1186/s13046-022-02247-y |
Ejemplares similares
-
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2021) -
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma
por: Panera, Nadia, et al.
Publicado: (2017) -
Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2
por: Gnani, Daniela, et al.
Publicado: (2017) -
Epigenetic remodelling in human hepatocellular carcinoma
por: Braghini, Maria Rita, et al.
Publicado: (2022) -
New Insights on the Nuclear Functions and Targeting of FAK in Cancer
por: Pomella, Silvia, et al.
Publicado: (2022)